I’ve been a bit surprised about discontinuing RC110, thought bundling that for AML might have been a way to get to early license/partnership to bring in some cash, raise sp to a base where further cash raising could be done from a decent sp. and minimise dilution, to fund the bigger opportunities with RC220 in breast cancer+ cardio protect and FTO.
be interesting to see what comes of the retuned plan.
Ann: Appendix 4E & Annual Report, page-21
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.62 |
Change
0.015(0.93%) |
Mkt cap ! $272.6M | |||
| Open | High | Low | Value | Volume |
| $1.69 | $1.69 | $1.55 | $456.1K | 284.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 300 | $1.59 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.62 | 2660 | 1 |
View Market Depth
| Last trade - 15.58pm 30/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |